Stockwinners Market Radar for October 20, 2022 - Earnings, Upgrades downgrades, option trades, Best Stock Advisory Service

20:31 EDT Cathie Wood's ARK Investment bought 66.2K shares of Tesla today

18:02 EDT Snap says lots of headroom to grow content engagement - Says working to improve content diversity. Says there is "significant room" to grow advertising business. Plans to expand advertising tests in Spotlight in Q4. Expects Q4 revenue "to grow seasonally at a pretty good clip." Comments taken from Q3 earnings conference call.

17:51 EDT Walmart to pay $215M to resolve Florida opioid claims - Florida Attorney General Ashley Moody announced a statewide agreement with Walmart to dispense naloxone to first responders across Florida. The announcement comes as Attorney General Moody continues to fight the national opioid crisis. As part of those efforts, Walmart has agreed to partner with the state in dispensing naloxone to law enforcement and first responders across Florida. Attorney General Ashley Moody said, "From the beginning of my administration, I have been working to end the opioid crisis and help Florida communities recover. I'm grateful for Walmart stepping up and agreeing to partner with the state to provide law enforcement and first responders with much-needed Naloxone. This will greatly help in our continuing mission to end the opioid crisis and save lives." Walmart has agreed to dispense 672,000 naloxone kits the state procured as part of an earlier agreement to law enforcement and first responders across the state. Walmart will also be paying the state of Florida $215M in funds to fight the opioid crisis.

17:35 EDT Snap says advertising partners 'decreasing their marketing budgets' - In its Q3 investor letter, the company said, "Our revenue growth continued to decelerate in Q3 and continues to be impacted by a number of factors we have noted throughout the past year, including platform policy changes, macroeconomic headwinds, and increased competition. We are finding that our advertising partners across many industries are decreasing their marketing budgets, especially in the face of operating environment headwinds, inflation-driven cost pressures, and rising costs of capital. In some industries where topline growth remains strong, but businesses are experiencing input cost pressure due to inflation, we have observed reduced campaign budgets as businesses seek to offset input cost pressures. In many high growth sectors, businesses are reassessing investment levels amid the rising cost of capital. We experience this on our advertising platform in the form of decreased brand-oriented advertising spending, but also in the form of lower bids per action and lower overall campaign budgets."

17:14 EDT Immunic falls 78% after Phase 1b IMU-935 update saw no separation from placebo - Shares of Immunic are down 78% at $2.03 after the company's announced the outcome of a pre-planned interim group-level data analysis of its phase 1b clinical trial of IMU-935 in patients with moderate-to-severe psoriasis. The analysis revealed that the group averages for Psoriasis Area and Severity Index reductions in the two active arms did not separate from placebo at four weeks.

17:11 EDT CSX jumps 4.7% to $28.35 after Q3 earnings beat

17:01 EDT Srax receives Nasdaq listing determination, to request hearing and further stay - Srax announced that on October 14, 2022, the company received notice from the Nasdaq Listing Qualifications Staff indicating that the Staff had determined to delist the company's securities from Nasdaq unless the company timely requests a hearing before the Nasdaq Hearings Panel. The Staff's determination was based upon the company's non-compliance with the filing requirement set forth in Nasdaq Listing Rule 5250(c)(1). On October 12, 2022, the company filed its Annual Report on Form 10-K for the fiscal year ended December 31, 2021 with the Securities and Exchange Commission; however, the company has not yet filed the Quarterly Reports on Form 10-Q for the quarters ended March 31, 2022 and June 30, 2022 with the SEC. The company plans to timely request a hearing before the Panel and, in accordance with Nasdaq Listing Rule 5815(a)(1)(B), a stay of any further suspension or delisting action by Nasdaq at least pending the issuance of a decision and the expiration of any extension that may be granted by the Panel following the hearing.

16:55 EDT Lockheed Martin receives order for three more Orion spacecraft from NASA - Lockheed Martin is now under contract to deliver three Orion spacecraft to NASA for its Artemis VI-VIII missions for $1.99B, continuing the delivery of exploration vehicles to the agency to carry astronauts into deep space and around the Moon supporting the Artemis program. The Orion crew module pressure vessel for the Artemis III mission-the first vehicle under the Lockheed Martin OPOC contract-is undergoing assembly at NASA's Kennedy Space Center. Lockheed Martin has completed two Orion vehicles-EFT-1 which flew in 2014, and Artemis I, which is weeks away from its launch to the Moon-and is actively building vehicles for the Artemis II-V missions. In the future: NASA can order an additional six Orion missions. Lockheed Martin and NASA have reduced the costs on Orion by 50% per vehicle on Artemis III through Artemis V, compared to vehicles built during the design and development phase. The vehicles built for Artemis VI, VII and VIII will see an additional 30% cost reduction.

16:46 EDT Snap drops 25% to $8.03 after Q3 revenue miss, cautious Q4 outlook

16:41 EDT Vertex Energy Chairman Benjamin Cowart sold $574,035 in shares - Chairman of Vertex Energy (VTNR) Benjamin Cowart sold 71,132 shares of company stock at $8.07 per share on October 19, for a total transaction amount of $574,035.

16:35 EDT Hepion Pharmaceuticals publishes food effect study with rencofilstat - Hepion Pharmaceuticals announced that the peer-reviewed journal, Clinical Pharmacology in Drug Development, has published the results of a clinical trial examining the effect of food on the oral bioavailability of rencofilstat, the Company's lead drug candidate. The article reviews a Phase 1, randomized, open-label trial in healthy subjects which assessed the bioavailability of a single dose of rencofilstat in both fasted and high-fat conditions. "This study showed that taking rencofilstat with a high fat meal increases the absorption of this cyclophilin inhibitor and confirms the safety of the drug while providing the flexibility for patients to take rencofilstat with or without food," Patrick Mayo, PhD, Hepion's Senior Vice President, Clinical Pharmacology & Analytics. "The increased absorption did not cause toxicity, and it is possible the increased exposure with food could enhance rencofilstat's efficacy in those NASH and/or HCC patients who may be poor absorbers of the drug."

16:34 EDT Revlon announces NYSE's decision to delist its common stock - Revlon announced that on October 20, 2022, the NYSE Regulatory Oversight Committee's Committee for Review rejected the Company's appeal and affirmed the New York Stock Exchange Staff's decision to delist the Company's Class A common stock following the June 15, 2022 Chapter 11 filing by the Company and certain of its subsidiaries in the U.S. Bankruptcy Court for the Southern District of New York. Accordingly, the Company expects the NYSE Staff to make an application to the Securities and Exchange Commission to delist the Company's Class A common stock in the near future. In the meantime, the NYSE has suspended trading in Revlon's Class A common stock. The Company's Class A common stock is expected to trade on the OTC marketplace/pink sheets following the delisting.

16:32 EDT Americas Gold and Silver reports Q3 silver production 331K ounces - Americas Gold and Silver repeorted production for the third quarter ended September 30, 2022. Production results, outlook and costs throughout this release production results are based on the Company's 100% interest in the Cosala Operations and 60% interest in the Galena Complex. For Q3-2022, consolidated attributable production totalled approximately 331,000 silver ounces and 1,339,000 silver equivalent1 ounces. Silver production increased by 92% year-over-year and increased 11% quarter-over-quarter. Silver equivalent production increased by 365% year-over-year and was unchanged quarter-over-quarter. Silver production is expected to further increase in Q4-2022 as production ramps-up into the higher-silver grade Upper Zone of the San Rafael deposit at the Cosala Operations and the Galena Complex exploits higher-silver grade stopes. The Company estimates consolidated Q3-2022 cash cost2 per silver ounce of $10.01 per ounce and consolidated Q3-2022 all-in sustaining cost2 per silver ounce of $18.66 per ounce which increased quarter-over-quarter due to lower zinc and lead prices. Year-to-date, consolidated attributable production totalled approximately 931,000 silver ounces and 3,957,000 silver equivalent ounces at a cash cost per silver ounce of approximately negative $0.39 per ounce and consolidated all-in sustaining cost per silver ounce of $7.51 per ounce. The Company's 2022 silver equivalent production is expected to be towards the upper end of the guidance of 4.8 to 5.2 million ounces in 2022 with further increases projected at 7.0 to 7.4 million ounces in 2024, increases of approximately 240% and 375%, respectively, compared with 2021. The Galena Hoist project remains on track with installation expected in late October 2022 and commissioning scheduled to begin in December 2022.

16:28 EDT Whirlpool drops 5% to $125 after Q3 results miss estimates, FY22 guidance cut

16:21 EDT Newpark Resources to sell mineral grinding business to Cimbar for $66M - Newpark Resources announced that it has entered into a definitive agreement to sell substantially all the long-lived assets, inventory and operations of its Excalibar mineral grinding business to Cimbar Resources, a mineral-based additive solutions company based in Chatsworth, GA. As of September 30, 2022, Excalibar had approximately $65M of net capital employed. Under the terms of the agreement, Newpark expects to generate net cash of approximately $66M through a combination of net cash proceeds at closing and net collections of certain retained assets and liabilities, including accounts receivable and accounts payable. In connection with the sale transaction, Cimbar and Newpark have also agreed to enter into a long-term barite supply agreement for Newpark's U.S. drilling fluids business, with an initial term of four years following the closing of the transaction. The sale is expected to close in the fourth quarter and remains subject to the closing conditions specified in the purchase agreement. Proceeds from the sale are expected to be used for general corporate purposes, including debt reduction, potential growth investments and/or share repurchases under the Company's current share repurchase program as the company continues to execute on its strategic plan.

16:17 EDT Snap: 'Highly likely' y/y revenue growth will decelerate throughout Q4 - Internal forecasts assume y/y revenue growth will be approximately flat in Q4, and Adjusted EBITDA would be approximately $200M under that revenue assumption for Q4. Q4 revenue consensus is $1.38B.

16:17 EDT Geospace signs $7.3M deep water ocean bottom node rental contract - Geospace Technologies announced an extended duration rental contract with an international marine geophysical services provider who will rent OBX deep water ocean bottom wireless seismic data acquisition nodes. Based on current contract terms, the value of the agreement is estimated at $7.3 million.

16:16 EDT Snap: Forward-looking revenue visibility 'incredibly challenging' - "As we look toward Q4, we are pleased with the growth we have observed in our community, and we estimate that DAU will be approximately 375 million in Q4. Thus far in Q4, we have observed revenue growth of approximately 9% year-over-year. Forward-looking revenue visibility remains incredibly challenging, and this is compounded by the fact that revenue in Q4 is typically disproportionately generated in the back half of the quarter, which further reduces our visibility. Given these factors, we do not intend to provide formal financial guidance for Q4. That said, we believe it is highly likely that year-over-year revenue growth will decelerate as we move through Q4, due in large part to the fact that Q4 has historically been relatively more dependent on brand-oriented advertising revenue, which declined slightly on a year-over-year basis in the most recent quarter. As a result, we have set our internal forecasts based on the assumption that year-over-year revenue growth will be approximately flat in Q4, and we estimate that Adjusted EBITDA would be approximately $200 million under that revenue assumption for Q4. We expect to incur the remainder of the transition costs associated with our strategic reprioritization in Q4 and estimate these costs will be between $20 and $35 million, which will therefore present a commensurate headwind to net income in the quarter."

16:15 EDT Snap: Business continued to face significant headwinds in Q3 - In its investor letter, Snap said its business continued to face significant headwinds in the third quarter. "We believe that we can be successful in this new operating environment - with elevated inflation, increasing interest rates, and heightened geopolitical tensions - by rigorously prioritizing our investments and continuing to delight our community with our products while driving success for our advertising partners." It added "While we are facing near-term headwinds to our revenue growth, we remain optimistic about our long-term opportunity based on the growth of our community and engagement. Today, we reach more than 75% of 13- to 34-year-olds in over 20 countries, representing over 50% of global advertising spend."

16:13 EDT Snap not providing guidance due to 'uncertainties' related to environment - Given uncertainties related to the operating environment, Snap said it is not providing expectations for revenue or adjusted EBITDA for the fourth quarter of 2022.

16:12 EDT Snap took action to further focus business, says CEO Spiegel - "This quarter we took action to further focus our business on our three strategic priorities: growing our community and deepening their engagement with our products, reaccelerating and diversifying our revenue growth, and investing in augmented reality," said Evan Spiegel, CEO. "The growth of our community to 363 million daily active users, an increase of 19% year-over-year, continues to expand our long-term opportunity as we navigate this volatile macroeconomic environment."

16:12 EDT Snap board authorizes $500M Class A stock repurchase program - Snap Inc. announced that its board of directors has authorized a stock repurchase program of up to $500M of its Class A common stock. Repurchases under the program have been authorized for the next 12 months but the program may be modified, suspended, or terminated at any time. The goal of the program is to utilize the company's strong balance sheet to opportunistically offset a portion of the dilution related to the issuance of restricted stock units to employees as part of the overall compensation program designed to foster an ownership culture. Repurchases under this program will be funded from existing cash and cash equivalents. As of September 30, 2022, Snap had $4.4B in cash, cash equivalents, and marketable securities.

16:10 EDT Ra Medical Systems expands U.S. customer base for VIVO - Catheter Precision "announces receipt of three commercial orders in the past 60 days as usage of the device continues to increase in the U.S. On September 12, 2022 privately held Catheter Precision announced a definitive merger agreement with Ra Medical Systems, which, if completed, will result in a combined publicly traded company focusing on the cardiac electrophysiology market. VIVO is a non-invasive 3D imaging system that enables physicians to identify the location of arrhythmias pre-procedure, streamlining workflow and reducing overall procedure time. The VIVO technology received FDA clearance at the end of 2020 with Catheter Precision initiating a limited strategic launch in the U.S. in 2021. To date VIVO has been utilized in more than 780 procedures worldwide. For the nine months ended September 30, 2022 Catheter Precision revenue from VIVO sales was approximately $190,000. Catheter Precision anticipates 2022 revenue in the range of $230,000 to $270,000."

16:09 EDT UFP Industries says has rising interest rates, historically high inflation - The company said, "We expect our balanced business model and operational improvements will continue to help us navigate new external challenges, including rising interest rates and historically high inflation. In the near term, we continue to expect more normalized demand in our largest segment, UFP Retail Solutions. For UFP Industrial, we continue to monitor business activity and the key economic indicators that drive this segment with many of those metrics remaining mixed. Pricing remains healthy as we pass through inflationary costs and benefit from our focus on value-added products. For UFP Construction, we see continued activity in commercial and infrastructure end markets and expect our exposure to a projected softening in the housing market to be somewhat offset by favorable demographic trends in the markets we serve and our participation in more affordable housing and the multifamily market. Our diversified business and strong track record of executing our strategy gives us confidence that we can continue to successfully navigate various market environments while delivering returns to shareholders."

16:08 EDT Sterling Construction's E-Infrastructure Solutions awarded $309M in Q3 - Sterling Infrastructure "announced that its E-Infrastructure Solutions segment reported new awards totaling $309 million during the third quarter of 2022. Sterling's E-Infrastructure projects include large-scale site development services for warehouses, data centers, e-commerce distribution centers, multi-use facilities and industrial facilities. E-Infrastructure is the Company's fastest-growing segment, continuing to solidify Sterling's leading market position."

16:04 EDT NYSE announces decision to suspend and remove Revlon - The New York Stock Exchange announced that the staff of NYSE Regulation has determined to suspend trading in the Class A Common Stock of Revlon - ticker symbol REV - from the NYSE. Trading in the company's Class A common stock was suspended after the market close on the NYSE on October 20. The staff suspended trading in the company's Class A common stock because the Committee for Review of the Board of Directors of the Exchange had issued a decision in which it upheld the Exchange's previously announced determination to delist the company's Class A common stock. The NYSE previously announced on June 16 that it had commenced delisting proceedings with respect to the company's Class A common stock that same day, after the company had disclosed its intention to file for protection under Chapter 11 of the Bankruptcy Code. The company had the right to request a review of this delisting determination by the Committee. Accordingly, the NYSE has suspended trading in the Class A common stock and will now file a delisting application with the Securities and Exchange Commission.

15:20 EDT Harbor Custom Development to sell 56.6 acres of land in Florida for $7.25M - Harbor Custom Development announced it has contracted to sell 56.6 acres of land in Punta Gorda, Florida for $7.25M to Historical Fund. The property is scheduled to close on or before December 20, upon the buyer's satisfaction of their due diligence requirements. "The potential sale of our Punta Gorda property reinforces our stated business plan to monetize our assets at the most opportune time in the development cycle by taking into account current market dynamics and our planned capital allocation strategy," stated Jeff Habersetzer, COO of Harbor Custom Development.

14:52 EDT PDS seeing 'uniform data' across clinical trials, CEO says - PDS Biotechnology (PDSB) is a clinical-stage immunotherapy company developing targeted immunotherapies for cancer and infectious disease. In an exclusive interview with The Fly, PDS Biotechnology CEO Frank Bedu-Addo discussed misconceptions around the company and the space: "When it comes to T-cell activating immuno-therapies, there hasn't been an FDA approval in over 10 years. Naturally, there's skepticism in the investor community around T-cell activating technology, which is too be expected. However, what cures all skepticism? Data! To date, we have administered PDS0101 to over 120 patients. We've reported data in almost 100 patients. The data has been very compelling, with us seeing uniform data across both trials. We're going to operate and generate that data, and hope in the near-future the real potential of the technology will become clear." "Meet the Company" is The Fly's recurring series of exclusive short interviews with Executive Officers to offer a deeper look inside the company.

14:44 EDT Revlon trading halted, news pending

14:34 EDT PDS' Bedu-Addo says data from PDS0101 HPV trials 'very promising' - PDS Biotechnology (PDSB) is a clinical-stage immunotherapy company developing targeted immunotherapies for cancer and infectious disease. In an exclusive interview with The Fly, PDS Biotechnology CEO Frank Bedu-Addo discussed the company's ongoing trials for its lead candidate PDS0101: "PDS0101 is our lead program and it is being developed to treat cancers that have been caused by the Human papillomavirus, or HPV. The first trial we've run -- the VERSATILE-002 -- we're combining our PDS0101 with Merck's [MRK] Keytruda. These are patients who failed initial treatment, whose disease has continued to progress or have had a recurrence of the disease. With Keytruda alone, study shows only 17% of patients have a response, which is a pretty low number. This is a very difficult to treat cancer. So, we said, with our Versamune technology, if we train PDS01010 to target HPV associated cancers, can we increase the number of patients with a response over 17%? The early data shows we have gone from 17% to 41%, which is more than doubling the rate of patients responding to this treatment. Typically, when you combine cancer treatments what happens is you made the combination of drug more toxic. What we have shown with the first 43 patients is that we have actually eliminated the severe adverse events associated with Keytruda as a single agent drug. From our 43 patients, not a single patient has had a severe adverse event to date. It's still early data but very promising. The second trial is the one being run by the National Cancer Institute and here we're looking at all HPV associated cancers, not only head and neck. We're looking at a very similar population: patients who failed chemotherapy, failed radiation treatment, and their next in line treatment would be a checkpoint inhibitor traditionally. And we asked, can we also include our second technology to expose even more tumors than checkpoint inhibitors alone can? That's a three-drug combination. We are now exposing more tumors to the immune system than the checkpoint inhibitor can do alone. So, checkpoint inhibitor alone [response] is 17%, with PDS0101 is 41%, and now with this triple combination the response rate is 88%, which is practically unheard of. This was the data we recently presented. Additionally, 25 months later, 75% of those patients are still alive. If you look at Keytruda in combination with chemotherapy, the overall survival of these patients is about 12 months. Very encouraging early data. But the National Cancer Institute went a step forward, even in more difficult to treat populations: let's look at patients who failed chemotherapy, who failed radiation and also failed checkpoint inhibitor therapy. These are the patients who are essentially at the end of the line with no FDA approved treatment for these patients. Their historical survival is 3 to 4 months. These patients would go to get maybe some extreme chemotherapy or some checkpoint inhibitor and the response in these patients is about 5%. In this triple combination, at the optimal doses of the three components, we've seen a 63% response rate. As reported, 16 months later 66% are still alive. The next step for us for both of these trials is to go into registrational trials, a Phase 3 trial, that could lead to commercialization. We've had early conversations with the FDA for on the first one - in combination with Keytruda, and we're hoping to have discussions with the FDA regarding the triple combination before the end of the calendar year. With our cervical cancer trial, the one being run by MD Anderson, they are expecting to provide the first data at the ISCT conference in November.They're combining PDS0101 with chemo-radiotherapy." "Meet the Company" is The Fly's recurring series of exclusive short interviews with Executive Officers to offer a deeper look inside the company. The remainder of this interview to follow.

14:17 EDT Novavax announces details on presentations at IDWeek 2022 - Novavax detailed that it will present new data from the Phase 3 PREVENT-19 trial evaluating its protein-based COVID-19 vaccine, NVX-CoV2373, as a booster in adults, including a breakdown by age and by booster dose interval - 8 and 11 months - at IDWeek 2022, October 20 to 22. Novavax said it will also present data from the first Phase 1/2 COVID-19-Influenza Combination (CIC) vaccine dose-finding trial. "New data will be presented from the PREVENT-19 trial, including an evaluation of the effect of age and schedule on boosted immunologic response. These data showed that following a booster dose, anti-spike antibody and neutralizing responses for the original prototype strain increased significantly relative to pre-boost levels, regardless of the dosing regimen or age group across adult participants. Antibody responses against the more recent Omicron variants, including BA.1, BA.2, and BA.5, approximated those associated with protection in the PREVENT-19 trial. These data will be presented in addition to data shared earlier in the month," the company stated. "At IDWeek 2022, we will share additional insights on the Novavax COVID-19 vaccine as an adult booster dose and show how we are further developing our portfolio with data from the first COVID-19-Influenza Combination vaccine candidate," added Gregory Glenn, M.D., President, Research and Development, Novavax.

13:59 EDT PDS CEO hopes technology's real potential becomes clear in near-future

13:59 EDT PDS expecting to move into Phase 1/2 trial for PDS0102 in 2024

13:59 EDT PDS Biotechnology CEO says early data from VERSATILE-002 trial 'very promising'

12:20 EDT Par Pacific trading resumes

12:05 EDT Par Pacific to acquire ExxonMobil Billings refinery, associated assets - Par Pacific Holdings (PARR) announced that it has signed a definitive agreement to acquire the 63,000 bpd Billings refinery and associated marketing and logistics assets from ExxonMobil (XOM) and two of its subsidiaries for a base purchase price of $310M, plus hydrocarbon and other inventory to be valued at closing. Par Pacific expects to fund the acquisition with cash on hand and availability under existing credit facilities, based on liquidity of approximately $495M on September 30. Hydrocarbon inventory is expected to be financed by a new working capital facility. The transaction is expected to be immediately accretive to Adjusted Net Income and Free Cash Flow per share and is expected to close in the second quarter of 2023, subject to customary closing conditions. "This acquisition will significantly enhance our scale and geographic diversification and underpins our focus on pursing strategic growth initiatives. We look forward to welcoming the dedicated and highly skilled Billings employees to our team. This acquisition expands our fully integrated downstream network in the western United States," said William Pate, President and CEO of Par Pacific.

12:01 EDT Exxon Mobil to sell Billings refinery to Par Pacific - ExxonMobil (XOM) and its affiliates have reached an agreement with Par Pacific Holdings (PARR) for the sale of the Billings refinery and select midstream assets in Montana and Washington, ExxonMobil announced. The sales agreement includes the Silvertip pipeline, ExxonMobil's interest in the Yellowstone pipeline and Yellowstone Energy LP, and its interests in product terminals in both states. "Employees directly supporting these assets will be offered positions at Par Pacific. ExxonMobil remains focused on safe and reliable operations and ensuring compliance with commitments made to customers and the relevant government agencies and regulators. ExxonMobil will work with Par Pacific to carefully manage the transition with dedicated teams assigned to maintain customer, vendor, personnel, community relations and environmental protection, subject to applicable law. Par Pacific has agreed to continue to supply Exxon- and Mobil-branded service stations in the region. The transaction is expected to close in the second quarter of 2023, subject to standard conditions and applicable legal requirements, including approval from regulatory authorities," the company said. "ExxonMobil is focused on investing in facilities where we can manufacture higher-value products such as lubricants and chemicals. We have proudly operated the Billings refinery since 1949 and we thank our more than 300 talented employees for their dedicated service," added Karen McKee, president of ExxonMobil Product Solutions.

12:00 EDT Allstate falls -11.7% - Allstate is down -11.7%, or -$15.78 to $119.37.

12:00 EDT Ranpak Holdings rises 9.7% - Ranpak Holdings is up 9.7%, or 32c to $3.61.

12:00 EDT Vertiv Holdings rises 15.0% - Vertiv Holdings is up 15.0%, or $1.71 to $13.11.

11:47 EDT Peabody Energy trading resumes

11:36 EDT Pool Corp. sees new pool construction down in 10%-15% range

11:35 EDT Peabody Energy says third party reports of earnings 'are false' - Peabody issued a statement stating that third party reports of earnings for the quarter ended September 30, 2022 are false as the company has not yet issued earnings for this period. The Company will report earnings in the coming weeks, consistent with past practice.

11:02 EDT Arrival Group to refocus resources on U.S. market - Arrival announced a proposal that would see the company refocus its resources on the U.S. market. The company stated in a press release: "Arrival has achieved critical milestones this year including Bus and Van certification in Q2 and produced the first production verification L Van in the Bicester Microfactory in Q3 which proves a vehicle can be assembled in a microfactory. In August, the Company announced plans to use existing cash on hand of $513M plus funds available through a $300M At the Market Platform to deliver the first vehicles to UK customers this year, invest in hard tooling and launch the Charlotte microfactory next year. At the end of Q3, the Company had existing funds of approximately $330M cash on hand and due to the current share price and daily trading volumes, has not found the ATM to be a reliable source of capital. Scaling production in the Bicester microfactory requires significant further investment in hard tooling and working capital and the Company has determined that the benefits of such an investment would be best directed to the US market. As a result, today the Company announced a plan to restructure its business to focus resources on a family of Van products for the US market as well as its enabling technologies - including core components, composite materials, mobile robotics, and software-defined factories. The Company will continue to produce a small number of Vans in Bicester to optimize microfactory processes and support trials with customers. The major factors in the Company's decision to shift focus to developing its US business included the tax credit recently announced as part of the Inflation Reduction Act - expected to offer between $7,500 to $40,000 for commercial vehicles, the large addressable market size, and substantially better margins. The business plans to raise capital to fund the commercialization of these vehicle programs in the US and is exploring all funding and strategic opportunities needed to bring the Vans designed for the US into production at the company's second Microfactory in Charlotte, North Carolina. In order to extend the company's cash runway, Arrival plans to further right-size the organization and cut cash intensive activities while continuing to advance its core technologies. The result of these proposals is expected to have a sizable impact on the Company's global workforce, predominantly in the UK. A business review will be provided during Arrival's third quarter 2022 financial results webinar on November 8."

10:56 EDT ASAP.com launches home, office delivery in NYC - ASAP.com has officially launched home and office delivery in New York City. ASAP brings a new choice for customers looking for a best-in-class delivery service that already has close ties to the city. Earlier, ASAP.com secured the exclusive mobile ordering rights with MetLife Stadium, the New York Giants and the New York Jets, and started food delivery in multiple cities in New Jersey.

10:30 EDT India's CCI imposes fine on Google for anti-competitive practices - The Competition Commission of India has imposed a penalty of Rs. 1337.76 crore on Google for "abusing its dominant position in multiple markets in the Android Mobile device ecosystem, apart from issuing cease and desist order. The Commission also directed Google to modify its conduct within a defined timeline," the regulator announced. Reference Link

10:23 EDT Texas AG sues Google for 'unauthorized' use of biometric data - Texas Attorney General Paxton has sued Google, alleging that the tech giant has unlawfully captured and used the biometric data of millions of Texans without properly obtaining their informed consent to do so. The lawsuit alleges that Google collected millions of biometric identifiers, including voiceprints and records of face geometry, from Texans through its products and services like Google Photos, Google Assistant, and Nest Hub Max. Google's exploitation of the personal information of Texans for its own commercial interests is a knowing violation of the state's Capture or Use of Biometric Identifier Act, the AG said in a statement. "Google's indiscriminate collection of the personal information of Texans, including very sensitive information like biometric identifiers, will not be tolerated," Attorney General Paxton said. "I will continue to fight Big Tech to ensure the privacy and security of all Texans." Reference Link

10:18 EDT Freeport-McMoRan 'realistic' about macro conditions creating uncertainties

10:09 EDT Freeport-McMoRan 'confident' in outlook, position of copper markets, says CEO

10:04 EDT Freeport-McMoRan: Macroeconomic sentiment continues to be weak

10:03 EDT Lithia & Driveway acquires Airstream Adventures - Lithia & Driveway announced it has acquired Airstream Adventures, which it identifies as "the largest Airstream dealer group in the nation for the iconic 'silver bullet' Airstream travel trailer." Airstream Adventures is headquartered in Portland, Oregon with locations throughout the Pacific Northwest and Northern California in markets including Portland, Seattle, Boise, Spokane, San Francisco, and Morgan Hill. "We are delighted to welcome the Airstream Adventures stores and its founder, Ted Davis, to our growing Lithia & Driveway family. Ted and his high performing team have done an exceptional job building the nation's largest exclusive dealer group. We are committed to becoming a steward of the iconic Airstream brand, ensuring that consumers will continue to create memories and adventures that last for generations," said Bryan DeBoer, Lithia & Driveway President and CEO.

10:00 EDT Freeport-McMoRan sees FY22 CapEx $2.7B excluding smelter projects - Sees FY copper sales of 4.2B lbs, with gold sales of 1.8M ozs, and molybdenum sales of 76M lbs. Comments taken from Q3 earnings conference call presentation slides.

10:00 EDT Allstate falls -10.4% - Allstate is down -10.4%, or -$14.02 to $121.13.

10:00 EDT AT&T rises 7.2% - AT&T is up 7.2%, or $1.11 to $16.65.

10:00 EDT AMTD Digital rises 9.9% - AMTD Digital is up 9.9%, or $2.69 to $29.80.

09:47 EDT Nokia falls -8.3% - Nokia is down -8.3%, or -38c to $4.18.

09:47 EDT Nouveau Monde rises 7.7% - Nouveau Monde is up 7.7%, or 38c to $5.32.

09:47 EDT Diebold rises 12.3% - Diebold is up 12.3%, or 33c to $3.01.

09:38 EDT Elix extends agreement for use of Neonode technology in displays - Neonode announced that Elix Systems SA has extended its agreement with Neonode and will increase the use of Neonode's Touch Sensor Modules to enable touch interaction on displays in medical ultrasound systems. The new agreement covers deliveries during 2022 and 2023 with a total value of over $400,000.

09:36 EDT AT&T says evaluating ways to expand fiber outside company's markets - Says company's fiber taking broadband market share from cable. Expects to grow earnings, free cash flow in FY23. Says seeing bill payments returning to pre-pandemic levels.

09:29 EDT Xponential Fitness signs master franchise pact in Kuwait - Xponential Fitnes announced it has signed a Master Franchise Agreement in Kuwait for its brands Rumble, Club Pilates, StretchLab and CycleBar. The deal, signed with Kuwait Real Estate Company, Aqarat, will result in the opening of a minimum of eight studios early in the initial 10-year term of the agreement, with additional studios to be developed based on market opportunity. The Master Franchisee for Xponential in Kuwait is the publicly traded real estate development company, Aqarat, a prominent developer and manager of commercial, residential and hospitality properties in Kuwait and the Middle East, as well as Europe and the United States. Aqarat also has investments and joint venture agreements with the hospitality brands Yotel, Courtyard by Marriott, and IFA Hotels and Resorts

09:18 EDT NextPlay's NextFintech division receives $15M strategic investment - NextPlay Technologies announced that it has entered into a binding commitment for a $15M strategic investment into its NextFintech Division from an institutional investor. This investment commitment consists of the purchase of shares of common stock in NextFintech at a pre-money valuation of $150 million for NextFintech, warrants to purchase shares in NextPlay beneficially owned by NextBank and an option to convert said NextFintech shares into up to an 18.8% equity interest in NextBank. "In spite of the challenging market conditions, we see immediate growth and profitability potential in our NextFintech division, which has been configured to serve overseas markets," stated Nithinan Boonyawattanapisut, NextPlay's principal executive officer. "Over the next 6 months, we will focus our resources on achieving group profitability via the NextFintech division. Concurrently, our HotPlay division is working on partnership deals and preparing for commercial launch of our in-game advertising platform from which is expected to start generating revenue next year. This potential financing, combined with our recent news of an up to $200,000,000 revolving credit facility at our NextBank, are remarkable achievements in these poor capital market conditions, and I laud the NextFintech division management team. We look forward to very near-term expansion in NextBank from a B2B model, serving corporations and family offices to a B2C model, by mid next year, which will allow us to take another significant leap in terms of growth at scale."

09:16 EDT Starry Group Holdings trading resumes

09:15 EDT Manitex announces realignment of Illinois-based operations - Manitex International announces a realignment of its Illinois-based operations to expand North American distribution and support of its Valla and Oil & Steel product lines. The changes allow for the efficient repurposing of resources toward the sale, distribution and support of Manitex aerial work platforms and electric crane product lines. The company's wholly owned subsidiary, Crane & Machinery "C&M", effective January 1st 2023, will transition from a multi-product sales and support organization to a direct channel distributor and factory representative for the Company's Oil & Steel and Valla products. Distribution will initially be supported by Manitex's team in Illinois and is anticipated to be augmented by newly appointed and future dealers of these products in North America. Crane & Machinery will become integrated with Manitex North America, leveraging the strength of the Manitex brand, while offering customers strong regional support of the product.

09:15 EDT Starry announces Q3 operational results - Starry announced operational results for Q3, which show that Starry successfully delivered strong growth in customer relationships to 91,297, while also increasing the number of homes serviceable to 5.96M and driving penetration of homes serviceable. Starry also announced that its digital equity program, Starry Connect, now reaches more than 87,000 units of public and affordable housing, an 83% increase year-over-year.

09:13 EDT Benefitfocus announces enhancements to Benefitplace platform - Benefitfocus has taken several steps to support a seamless open enrollment experience this fall. These include new features, resources and enhancements to its Benefitplace platform that are designed to enhance the user experience and further reduce administrative complexity for benefits managers.

09:11 EDT Sidus Space signs launch agreement with Vaya Space - Sidus Space announced that it has signed a launch agreement with Vaya Space for four launches over multiple years. This agreement expands Sidus Space's ability to deliver satellite services. Sidus Space recently announced a launch agreement with SpaceX for a total of five expected launches in the next 13-15 months. In addition, as an ISS implementation partner, Sidus also has the ability to launch from the ISS which creates multiple paths to orbit for LizzieSat with the signing of this launch agreement with Vaya Space. LizzieSat is Sidus' 100kg, partially 3D printed, small satellite for its planned multi-mission LEO satellite constellation. Sidus Space has an approved International Telecommunication Union, or ITU, Spectrum license for multiple altitudes and inclinations. LizzieSat satellites will fly custom payloads tailored to maximize customer return on investment.

09:10 EDT WisdomTree to transfer listing to NYSE, trade under WT ticker symbol - WisdomTree Investments announced that it is transferring the listing of its common stock to the New York Stock Exchange from The Nasdaq Global Select Market. WisdomTree anticipates its common stock will begin trading on the NYSE at market open on Monday, November 7, 2022, under the new ticker symbol "WT". The Company's common stock will continue to trade under the ticker symbol "WETF" on Nasdaq until the close of the market on Friday, November 4, 2022. The Company also will change its corporate name from WisdomTree Investments, Inc. to WisdomTree, Inc. effective November 7, 2022.

09:09 EDT Hudson Pacific promotes Drew Gordon to CIO, Andy Watula to COO - Hudson Pacific Properties announced the promotions of Drew Gordon, formerly Executive Vice President for California Office Operations, to Chief Investment Officer, and Andy Wattula, formerly Executive Vice President for Pacific Northwest/Canada Office Operations, to Chief Operating Officer. "Drew and Andy are tenured executives who have demonstrated their ability to strategically lead Hudson Pacific's investments and operations functions, respectively," said Victor Coleman, Chairman and CEO for Hudson Pacific. "This expanded organizational structure will support efficient decision-making and add value over the long term as we leverage our unique expertise and relationships to deliver world-class office and studio facilities." As Chief Operating Officer, Wattula will oversee operations for the company's entire office portfolio. Wattula joined Hudson Pacific in 2017 and has been instrumental in the success of the company's Seattle and Vancouver operations. Prior to Hudson Pacific, Wattula was a Senior Vice President with Beacon Capital Partners and a Director at Hines. He also served as a Naval Flight Officer in the United States Navy. As Chief Investment Officer, Gordon will oversee acquisitions and dispositions for Hudson Pacific. Gordon has been with Hudson Pacific since 2011 and has led operations throughout California and in Seattle. Prior to Hudson Pacific, he held executive positions at real estate firms including Venture Corporation, ATC Partners and SKS Investments.

09:08 EDT Hershey signs new solar power purchase agreement with National Grid Renewables - Hershey announced a 140 MW Power Purchase Agreement with National Grid Renewables for Copperhead, the second PPA between Hershey and National Grid Renewables after Hershey's Noble solar PPA announced in 2021. National Grid Renewables recently started construction at its Copperhead Solar & Storage Project, a 150 MW solar and 100 MWh storage project in Falls County, Texas. Copperhead will utilize Series 6 thin film solar modules developed and produced by First Solar (FSLR).Copperhead is projected to produce an estimated $25M in direct economic impact throughout its first 25 years of operation, including the production of new tax revenue, onsite operations jobs, and the creation of a charitable fund estimated at $600K. Hershey is on track to achieve its greenhouse gas emissions targets, having reported a 48% reduction in Scope 1 and 2 emissions against a 2018 baseline and a 18% reduction in Scope 3.

09:07 EDT AgriFORCE selects New Engen to support launch of Awakened Grains - AgriFORCE announced that it has selected New Engen, to support the upcoming launch of un(Think) Awakened Flour. Working in partnership with AgriFORCE, New Engen will execute digital, social and influencer campaigns to support the Company's aim of driving e-commerce sales across multiple platforms. "The team at un(Think) has been laying the ground work for a successful consumer facing launch of un(Think) Awakened Flour, the first in a series of tasty, healthy, nutritious and low-carb products based on our proprietary and patent-pending process," said Hernando Ruiz-Jimenez, General Manager of un(Think) Foods. "We are delighted to partner with the team at New Engen, who bring a proven track record with many of the world's leading consumer brands. We look forward to working with them to enhance our digital marketing and direct-to-consumer strategy through performance media, influencer campaigns and more - helping drive online sales via our new e-commerce platform, powered by Shopify."

09:06 EDT Q2 Holdings BM, Technologies team on 'next-generation embedded finance' - Helix by Q2 (QTWO) and BM Technologies (BMTX), formerly known as BankMobile, have announced they are partnering to provide comprehensive embedded banking solutions for consumer brands, combining Helix's embedded finance platform and bank partnerships with BM Technologies' award-winning app development services and program management. The combined solution enables consumer brands to offer differentiated banking solutions that enhance their brand experience without having to build and manage it themselves. Helix offers the building blocks of banking - accounts, cards, payments, data controls, administrative tools and monetization solutions - all in one place, making it easier for fintechs and innovative brands to embed personalized financial experiences within their applications. Helix serves more than 13 million users, processing over $40B in transactions annually.

09:05 EDT STMicroelectronics announces smart wireless module STM32WB5MMGH6 - STMicroelectronics is helping increase industrial productivity and reduce waste and pollution with its smart wireless module. Conceived for Industry 4.0 applications, this module, the STM32WB5MMGH6, simplifies using ST's innovative wireless microcontrollers in powerful use cases like I-care Group's intelligent equipment condition monitoring.

09:04 EDT Magellan Midstream raises quarterly cash distribution to $1.0475 per unit - The board of directors of Magellan Midstream Partners, L.P. has declared a quarterly cash distribution of $1.0475 per unit for the period July 1 through Sept. 30. The third-quarter distribution is 1% higher than the $1.0375 paid for both second quarter 2022 and third quarter 2021. The new distribution, which equates to $4.19 per unit on an annualized basis, will be paid Nov. 14 to unitholders of record at the close of business on Nov. 7.

09:02 EDT AbbVie acquires DJS Antibodies for $255M - AbbVie acquired DJS Antibodies, a privately-held UK-based biotechnology company dedicated to discovering and developing antibody medicines that target difficult-to-drug disease-causing proteins, such as G protein-coupled receptors. DJS's lead program is DJS-002, a potential first-in-class lysophosphatidic acid receptor 1 antagonist antibody currently in investigational preclinical studies for the treatment of Idiopathic Pulmonary Fibrosis and other fibrotic diseases. AbbVie will pay DJS shareholders approximately $255M in cash at closing for the acquisition of DJS. DJS shareholders remain eligible for potential additional payments upon the achievement of certain development milestones related to the success of the DJS-002 program. AbbVie anticipates retaining all current DJS employees and its facility in Oxford. DJS is backed by founding investors Oxford Science Enterprises and Johnson & Johnson Innovation, along with LifeArc, Sedgwick Yard and Amgen Ventures.

09:02 EDT Remitly Global announces key business milestones in APAC region - Remitly Global announced key business milestones in the Asia-Pacific, APAC, region. Remitly has expanded its global footprint to include Japan and New Zealand. To date, Remitly has helped customers send $2.5B in remittance volume from APAC, and the company is poised for further growth as access to its trusted platform becomes available to millions of new customers in the region. "Remitly is proud to serve immigrants living in Asia and the greater Pacific region and to leverage the investments we've made in our global payments platform to be the trusted provider for customers sending money home to their loved ones," said Matt Oppenheimer, co-founder and CEO, of Remitly. "We are on a mission to transform international payments. Helping customers send more than $2.5 billion from the region to date is a testament not only to strong demand, but also to the world-class customer experience Remitly provides, making the process of getting money home faster, simpler, and more reliable."

08:57 EDT American Airlines: Pilot issues to take 2-3 years to work out

08:54 EDT Telos gets TSA approval to operate PreCheck System - In an 8-K filing yesterday, the company stated: "On October 18, 2022, the Transportation Security Administration issued an authority to operate to Telos Identity Management Solutions, LLC for Telos' PreCheck System. With TSA approval, Telos is providing its TSA PreCheck(R) enrollment services for a trial period to a limited population of applicants in order to validate systems and processes in advance of its full implementation as an authorized TSA PreCheck(R) enrollment provider. Once Telos successfully completes its trial period to the satisfaction of TSA, Telos will launch its services to the public more widely. Telos continues to anticipate this launch will occur in calendar year 2022."

08:48 EDT American Airlines sees FY23 capacity 95%-100% of 2019 levels

08:47 EDT American Airlines sees Q4 TRASM 18%-20% higher than 2019 - CASM-ex fuel is expected to be up 8%-10% vs. 2019 levels.

08:47 EDT AT&T continues to expect FY22 capital investments in '$24B range'

08:45 EDT American Airlines expects to take delivery of 19 737-8 Max aircraft in FY23

08:43 EDT Duos Technologies Group appoints David McKee to Industry Advisory Group - Duos Technologies Group announced the addition of David McKee to its newly formed Industry Advisory Group. The Industry Advisory Group's function will be to provide consultation on certain areas requiring specialist industry, technical or financial knowledge to assist senior management in strategic planning. Mr. McKee will be focused on the Company's roll-out of portals in the rail industry. Most recently, he was the Vice President of Rail Logistics for Oldcastle's Class III Railroad operations where he was responsible for managing safety, train operations, fleet productivity goals, and regulatory compliance.

08:42 EDT IntelGenx issued U.S. patent covering VersaFilm Technology - IntelGenx announced that the United States Patent and Trademark Office issued U.S. Patent No. 11,471,406 to IntelGenx, with claims for modulating drug absorption in oral film dosage form designed for sublingual administration of various pharmaceuticals, including some cannabinoids. This, the latest in a series of patents recently granted to IntelGenx, is expected to remain in force at least until 2038, not including any potential patent term extensions. The '406 patent issuance adds to the formidable intellectual property estate the Company has been building for its VersaFilm(R) oral film technology. This patent will enable development of a wide variety of protected product designed for improved drug delivery. While this novel proprietary technology covered by both U.S. Patent No. 10,828,254, previously granted to IntelGenx in November 2020, and the new '406 patent is suitable for cannabis-containing oral films, especially for THC oral film dosage forms, the '406 patent specifically covers an oral film dosage form designed for modulating absorption profile of sublingually administered actives.

08:42 EDT Lender One opens branded mortgage branch location at select Walmart store - Lenders One Cooperative, a managed by a subsidiary of Altisource Portfolio Solutions (ASPS), announces the grand opening of its second mortgage lender in-store branch location at a select Walmart (WMT) store in Boonton, NJ. This initial launch is part of Lenders One's nationwide initiative to offer prospective homebuyers access to mortgage origination solutions where they shop within their community. "Walmart has long been a trusted name for consumers, so seeing the branch in-store opportunity with Walmart come to fruition with MLB Residential Lending is an exciting move to connect lenders and borrowers at our second location in Boonton, NJ," said Justin Demola, CMB, President, Lenders One. "The physical in-store presence at Walmart allows Lenders One members to connect with the local community and help them learn about the mortgage process, become mortgage ready and achieve the American Dream of homeownership."

08:42 EDT Everbridge appoints Sheila Carpenter as Chief Information Officer - Everbridge announced the appointment of Sheila Carpenter as Chief Information Officer , responsible for leading the company's global information technology efforts, including corporate IT infrastructure, technology systems, and enterprise architecture. Sheila reports to Chief Executive Officer Dave Wagner, and will oversee teams led by the company's Chief Information Security Officer and Vice President of Enterprise IT.

08:41 EDT Fulcrum Therapeutics reports resignation of president of R&D - In a regulatory filing last night, Fulcrum Therapeutics disclosed that on October 14 Fulcrum and Dr. Judith Dunn entered into a separation agreement subsequent to Dr. Dunn's resignation from her position as president, research and development. "Dr. Dunn will remain employed with Fulcrum through January 3, 2023, and continue to provide biotechnology consulting services, including clinical development services, in a transitional capacity while Fulcrum continues its previously announced search for a Chief Medical Officer," the filing stated.

08:41 EDT Lamb Weston to buy remaining interest in European JV for EUR 700M in cash/stock - Lamb Weston Holdings announced it has entered into an agreement to purchase the remaining equity interests in its European joint venture with Meijer Frozen Foods B.V. for EUR 700M in cash and common stock of Lamb Weston. "Lamb-Weston/Meijer was built over the last 28 years, and we're grateful to Meijer Frozen Foods for their longstanding partnership," said Tom Werner, President and CEO of Lamb Weston. "The joint venture has served as a strong platform to drive growth in Europe and the Middle East, as well as to support our global customer base across our key international markets. This transaction firmly aligns with Lamb Weston's long-term capital allocation and acquisition framework, and we believe it will strengthen our manufacturing footprint by leveraging a truly global supply chain to better serve our customers and position us to take advantage of growth opportunities in Europe, the Middle East and Africa." "We're proud of the business we've built together to create a market leader in Europe," said Kees Meijer, CEO of Meijer Frozen Foods. "We remain confident in the long-term outlook for Lamb Weston and the global frozen potato category. By holding an investment in common stock of Lamb Weston after the transaction closes, we sustain our strong belief in a bright future for the business." Upon completion of the transaction, Lamb Weston will own 100% of Lamb-Weston/Meijer v.o.f. , formerly operated as a 50/50 joint venture between a wholly-owned subsidiary of Lamb Weston and Meijer Frozen Foods. Lamb Weston will pay transaction consideration of EUR 700 million, comprised of EUR 525 million in cash and EUR 175 million of Lamb Weston's common stock. The Company anticipates closing the transaction in the second half of fiscal 2023, subject to regulatory approvals. T The transaction will give the Company ownership of an additional five manufacturing facilities worldwide, including four facilities in the Netherlands and one in the United Kingdom, as well as a sixth manufacturing facility through a 75% interest in a joint venture in Austria. These facilities produce nearly two billion pounds of finished frozen products annually. In addition, upon completion of the transaction, the former joint venture's approximately 1,500 employees will become employees of Lamb Weston.

08:40 EDT American Airlines 'very bullish' about overall demand, says CEO Isom

08:39 EDT Predictive Oncology appoints Vennare as CEO, Chairman - Predictive Oncology announces the appointment of Raymond Vennare as Chief Executive Officer and Chairman of the Board, effective Nov. 1. Vennare will continue to work closely with the company's senior management to expand its portfolio of proprietary solutions to advance the pipeline of drug development in oncology, ranging from early discovery through clinical trials. Since 2015, Vennare has served as CEO and Chairman of Cvergenx and is currently an Investment Partner in Inventeur.

08:38 EDT Chewy expands CarePlus with new plan by Lemonade Pet - Chewy (CHWY) is expanding CarePlus, its exclusive suite of insurance and wellness offerings, with new plans provided by Lemonade Pet, Lemonade's (LMND) pet health insurance product. Through this partnership, millions of Chewy customers will have the ability to conveniently select and create customized plans to meet their unique needs. Pet parents will also benefit from all of Chewy's customer-forward pet health services - from access to veterinarians via its innovative telehealth service, "Connect with a Vet," to Chewy Pharmacy.

08:37 EDT ReShape announces release of positive consensus statement from ASMBS - ReShape Lifesciences announced that the American Society for Metabolic and Bariatric Surgery, ASMBS, has issued a Consensus Statement on Lap-Band use and aftercare management entitled, "American Society of Metabolic and Bariatric Surgery Consensus Statement on Laparoscopic Adjustable Gastric Band Management." In order to formulate its Consensus Statement, the ASMBS Integrated Health Clinical Issues Committee surveyed a total of thirty-nine Lap-Band surgeons and integrated health program members, considered to be experts in the management of Lap-Band patients. A formal modified Delphi, 2-stage consensus approach was conducted on Lap-Band management. Consensus was set a priori at 75% agreement, defined as the proportion of participants responding with agreement or disagreement on the Likert scale. "Having the Lap-Band recognized and endorsed in the new, Consensus Statement issued by ASMBS, one of the industry's most important and influential organizations, is another validation that the anatomy-sparing Lap-Band is a safe and effective weight loss solution. We are pleased to see that many of the determinations reached in the Statement, related to the six domains, align perfectly with ReShape's own evidence-based, best practices recommendations," stated Paul Hickey, President and Chief Executive Officer of ReShape Lifesciences. "The Consensus Statement issued by experts in the Lap-Band procedure has also concluded that proper aftercare, related to behavioral health and nutrition, is critical to the success of the weight loss procedure. We believe that our nationwide, reshapecare program aligns with this critical component of Lap-Band(R) treatment, through which we offer effective and convenient virtual health coaching for all weight loss patients including pre- and post-surgical bariatric patients. Additionally, our philosophy is to partner with organizations such as the ASMBS to identify and train surgeons, utilizing comprehensive programs, to have them provide the long-term care required to achieve safe, durable weight loss results."

08:35 EDT American Airlines CEO: Customers continue to value air travel post-pandemic

08:33 EDT Color Star Technology signs cooperation agreement for Color World Metaverse - Color Star Technology subsidiary Color Metaverse signed a strategic cooperation agreement with A-NEX Korea, a Korean company, in Dubai. The two sides will focus on further cooperation around the DONO Phone and the ColorWorld Metaverse. The two sides will formally discuss and develop cyber security technologies, metaverse project, and metaverse mobile communication strategy. A-NEX, a technology company, will also be joining the Color World platform. Color Star will create a metaverse headquarter for it, and will also include A-NEX projects along with it in the future. In addition, A-NEX will also provide cyber security technology to Color Star to strengthen the metaverse software application together with Color Star's technical team.

08:29 EDT Enzo Biochem appoints Eckert as interim CFO - Enzo Biochem announced the appointment of Patricia Eckert, CPA, as interim Chief Financial Officer, CFO. Eckert's appointment follows the resignation of David Bench, who is departing the Company effective November 14, 2022 to pursue a new opportunity. Eckert has spent the past five years in various finance roles with Enzo.

08:27 EDT Silo Pharma announces proof-of-concept data for SPC-14 - Silo Pharma announced proof-of-concept data supporting the therapeutic potential of SPC-14 as a treatment for Alzheimer's disease, as demonstrated in a mouse model. The research was conducted as part of a sponsored research agreement with Columbia University in New York. SPC-14, a novel drug that combines an FDA-approved therapeutic with ketamine, is in development for the treatment of dementia related to Alzheimer's disease. Initial data from its SPC-14 research studies shows that chronic dosing of SPC-14 resulted in increased memory in AD mice and had no negative weight effects on the subjects. Silo Pharma's Commercial Evaluation License Agreement with Columbia University grants an option to license two distinct assets currently under development: SPC-14 targeting Alzheimer's disease and SPC-15 targeting stress-induced affective disorders.

08:26 EDT Labrador Gold announces results from drilling at Kingsway project - Labrador Gold is pleased to announce results from recent drilling targeting the prospective Appleton Fault Zone over a 12km strike length. The drilling is part of the Company's ongoing 100,000 metre diamond drilling program at its 100% owned Kingsway Project. Highlights of the drilling include an intersection of 30.67 g/t Au over 1.1 metres from 208.85 metres that included 99.31 g/t Au over 0. 3 metres in Hole K-22-190 from the north end of Big Vein. The intersection is approximately 75 metres north of the discovery outcrop and is downdip of Hole K-22-177 that intersected the longest interval yet of 2.02g/t Au over 32m. Also at Big Vein, Hole K-22-194 intersected 1.27 g/t Au over 6.17 metres from 115 metres that included 2.3 g/t Au over 3m. At Big Vein Southwest, Hole K-22-184 intersected 4.67 g/t over 1.64m from 336.25m that included 8.97 g/t over 0.75m. "We continue to have drilling success at the north end of Big Vein where several significant intercepts have now been received, including 6.07 g/t Au over 19m in hole K-21-111 and 2.02 g/t over 32m in Hole K-22-177 and now 30.67g/t Au in Hole K-22-190," said Roger Moss, President and CEO. "The down dip mineralization in K-22-190 shows the high-grade prospectivity of this area which we are currently following up. Big Vein has been drilled over a strike length of approximately 520 metres and remains open both to the northeast and southwest. Two drill rigs are currently drilling at Big Vein to test for extensions of the mineralization in both directions."

08:23 EDT Larimar Therapeutics announces issuance of U.S. patent for CTI-1601 - Larimar Therapeutics announced the issuance of U.S. Patent No. 11,459,363. The patent, titled, "Materials and Methods for Treating Friedreich's Ataxia," provides composition of matter protection for CTI-1601 into at least July 2040. Larimar has an exclusive license to the patent per a prior agreement with Indiana University. In addition to, and independent of, patent protection, CTI-1601 should be eligible for seven years of orphan drug exclusivity and twelve years of reference product data exclusivity in the U.S. upon U.S. Food and Drug Administration approval and ten years of orphan drug and market exclusivity in the European Union upon European Medicines Agency marketing authorization.

08:22 EDT Appreciate announces planned board of directors - RW National Holdings announced that its board of directors following the close of the proposed business combination with PropTech Investment Corporation II is expected to include independent members with industry and public company experience. Appreciate currently expects its board of directors to include Laurie Hawkes, M. Joseph Beck, Gloria Fu and William Bush upon consummation of the proposed business combination. Upon consummation of the business combination, Appreciate expects that its board of directors would include the following persons: Laurie Hawkes, Chairman of the board of directors of Broadstone Net Lease, former co-founder, President & COO of American Residential Properties. It is expected that Ms. Hawkes will serve as Chairman of the Board. Christopher Laurence, CEO of Appreciate; former COO of Cydcor; former CEO, COO and CFO at ThreeSixty Sourcing. M. Joseph Beck, Co-CEO and CFO of PTIC; Managing Partner of Growth Strategies of Hennessy Capital Group; former Co-CEO of PropTech Acquisition Corp.; former Senior Investment Manager of ADIA. Gloria Fu, independent director at PTIC; former Managing Director of JPMorgan Asset Management; former Vice President & sell-side equity research analyst at JPMorgan Securities. Douglas Bergeron, member of the Renters Warehouse board of directors; Managing Director of Hudson Executive Capital; CEO of two special purpose acquisition companies; former CEO of Verifone. It is expected that Mr. Bergeron will chair the governance and nominating committee. Scott Honour, Chairman of the Renters Warehouse board of directors; Co-founder and Managing Partner of Northern Pacific Group; Chairman of Perception Capital Corp. II; former Senior Managing Director at The Gores Group, a private equity firm.William Bush, CFO of Stem since leading its public listing via a reverse merger with a special purpose acquisition company; former CFO of Borrego Solar Systems. It is expected that Mr. Bush will chair the audit committee. Marcy Haymaker, Partner at Northern Pacific Group; Director of Perception Capital Partners II; former Principal for Sustainable Opportunities Acquisition Corp.; former Associate at The Gores Group. It is expected that Ms. Haymaker will chair the compensation committee.

08:18 EDT Crown Electrokinetics issues letter to shareholders - Crown Electrokinetics released a letter to its shareholders. "I am pleased to announce that, in an extremely challenging market for pre-revenue companies, we have successfully closed on $4 million of fresh capital. This new capital will allow Crown to deliver its first-generation product, while also providing us with the runway to continue negotiating debt capital, which the Company will require to initiate our next phase of manufacturing... Crown remains hyper-focused on executing against our strategic goals and delivering our Smart Window Inserts to the market... According to a recently issued report by MarketsandMarkets, the smart glass market is predicted to be worth $8.2 billion by 2027, at a CAGR of 10.4%... We believe we have the right solution at the right time and are well positioned to capitalize on this forecasted strong smart glass growth trend. Organizationally, we are also taking proactive efforts to ensure we have the optimal structure for the future. As part of this transition, Edward Kovalik, President and board member, will depart, along with board members Gary Hanna and Gizman Abbas... Daniel Marcus will join the board as an independent board member..."

08:16 EDT Cyngn signs commercial ontract with HEVI, no terms - Cyngn announced it has signed a contract with HEVI, a manufacturer of electric industrial vehicles under Greenland Technologies Holding Corporation, to be HEVI's exclusive supplier of vehicle tracking systems.

08:15 EDT electroCore announces data from its nVNS treatment of TBI - electroCore announced data from an oral presentation at Neurocritical Care Society's, NCS, 20th Annual Meeting held in San Antonio, Texas on October 17 - 21, 2022 on the possible role of gammaCore, nVNS, in the acute treatment of Traumatic Brain Injury, TBI. The study design included low dose nVNS, high dose nVNS, and control arms, and stimulated 5 or 10 times over an hour, beginning 30 minutes post-TBI in a rodent model. Magnetic Resonance Imaging studies on Day 1 and 7 revealed smaller brain lesion volume among the nVNS groups compared with the control group. On Day 1, these abnormal volume changes were 13% and 55% smaller in the lower dose and higher dose nVNS groups, respectively, compared with the control group. By Day 7, nVNS decreased the size of the cortical lesion by 35% and 89% in the low dose and high dose nVNS groups, respectively, compared with the control group. The control group showed significant deficits in 3 common neurobehavioral assessments including rotarod, anxiety, and modified beam walking performances. All these deficits were significantly reduced in the high dose nVNS group on Day 1 and the two anxiety indices were also reduced on Day 7 post-injury compared with the control group. MRI data suggest that the benefits may be caused by a decrease in the deformation and swelling of brain tissue after TBI.

08:12 EDT Enphase Energy expands IQ8 microinverter deployments in Hawaii - Enphase Energy announced today that installers of Enphase products in Hawaii have seen growing deployments of the Enphase Energy System powered by IQ8 Microinverters as local policy continues to encourage the adoption of home solar and battery energy systems. "Enphase is dedicated to working with its top-tier installer network in Hawaii to deliver some of the most advanced, durable, and safe solar and battery technology solutions on the market," said Dave Ranhoff, chief commercial officer at Enphase Energy. "The IQ8 Microinverter paired with the IQ Battery offers energy independence and resilience to homeowners across the state. We stand ready to expand access to solar and batteries as Hawaii works toward its goal to reach 100 percent renewable energy by 2045."

08:12 EDT Verses Technologies completes Autonomous Drone test in Zaragoza, Spain - VERSES Technologies announced the completion of its first-of-a-kind Autonomous Drone or Urban Air Mobility test in Zaragoza, Spain. As part of Flying Forward 2020, a European Commission-funded special research and innovation project developing Urban Air Mobility infrastructure, and in collaboration with the Zaragoza City Council and first responder teams, VERSES successfully deployed multiple autonomous drones to provide real-time aerial views in order to monitor the safety of hundreds of thousands of visitors participating in the cultural procession that runs through the streets of Zaragoza during the festival of La Virgen del Pilar. Utilizing VERSES' real time mobility portal, powered by the company's AI operating system, COSM, local authorities were able to remotely monitor the entire celebration at the Plaza del Pilar Square and surrounding neighborhoods. Working with the Zaragoza City Council and its own legal advisors, VERSES' COSM operating system employs artificial intelligence and digital twins to govern the behavior of the autonomous drones to ensure strict compliance with the air traffic regulation and data privacy laws. The COSM-enabled autonomous drones used in this UAM mission provided continuous, real-time monitoring of the flow of traffic, safety and security assessments and the ability to proactively identify unusual or atypical occurrences, reducing the need for extra monitoring teams on the ground and air. In addition, the COSM AI-platform ensured the governance of the autonomous drone flights were in compliance with all local laws, data management policies and security regulations, a first of its kind real-world demonstration of the goals set out by the European Commission to enable automated compliance of AI powered drones within the European Union.

08:10 EDT Yoshitsu announces opening of new retail store in Hong Kong - Yoshitsu announced the grand opening of its new retail store in Hong Kong on October 20, 2022. The Store is located at Unit 29, Citylink Plaza, 1 Shatin Station Circuit, Shatin, New Territories, Hong Kong. Citylink Plaza stands above the Shatin railway station, which provides a convenient location for the local community. Mei Kanayama, the Principal Executive Officer of Yoshitsu Co., Ltd, commented, "We are excited to serve our customers in Shatin and provide them with valuable products and services. We expect to help customers explore various Japanese brands among the beauty products and sundry products. In addition, we will continue to provide personalized assistance services to meet the needs of the Shatin community we serve. The Citylink Store is one of the new stores we expect to open this year. We look forward to continuing our expansion efforts in the future, strengthening our store network and raising our brand awareness."

08:08 EDT Vizio leverages SpringServe Tiles to enhance content discovery - SpringServe, a part of Magnite (MGNI), announced that VIZIO(VZIO) will be leveraging the SpringServe Tiles solution to enhance the content discovery experience. Tiles gives publishers flexibility to showcase custom creative within the streaming interface in any size and a wide variety of formats. Publishers can use the functionality to highlight content recommendations or feature non-intrusive display advertising. "We created Tiles to bring the precision of video ad serving to the content discovery experience users see when they turn on their connected TVs," said Joe Hirsch, General Manager of SpringServe. "This technology, built off the IAB native ads spec, brings new tools to the most important first impression consumers have with their television, the navigation of the home screen. CTV Native Tiles gives TV manufacturers like VIZIO additional non-interruptive ad experiences in the form of pause ads and sponsored scene selection."

08:07 EDT DarioHealth announces two new employer contracts - DarioHealth announced the company's full suite of chronic condition management solutions were selected by two employers to help improve overall employee health beginning in the first quarter of 2023. The new accounts continue the rapid growth of Dario's business in the employer market and include a global Fortune 1000 company and a global sports organization. Both organizations selected Dario to help improve the health of employees living with diabetes, high blood pressure, weight management needs, musculoskeletal and behavioral health needs using the company's single digital therapeutics platform. The global company's adoption comes after Dario demonstrated the advantages of its platform in a several month pilot and represents Dario's ability to penetrate some of the largest self-insured employers.

08:05 EDT ReneSola announces 10 MWp inaugural IPP project in Hungary - ReneSola announced that the company has energized its first inaugural IPP project in Hungary in October. The project "Csomad 1-2" consists of two PV plants with total installed capacity of 10.2 MWp, equivalent to powering approximately 4,000 households per day. The project entered the commercial operation stage in the beginning of October.

08:05 EDT USPTO issues Lantern Pharma new patent for cancer drug candidate LP-300 - Lantern Pharma announced that the United States Patent and Trademark Office USPTO has issued U.S. Patent No. 11,471,431, for Lantern's drug candidate LP-300, which is in a Phase 2 clinical trial, Harmonic, for never-smokers with relapsed non-small cell lung cancer NSCLC. The patent is directed to increasing the survival time of cancer patients receiving LP-300 for cancers that are marked by overexpression of the regulatory proteins thioredoxin or glutaredoxin and/or exhibition of TRX- or GRX-mediated resistance to one or more chemotherapeutic interventions. TRX and GRX are commonly overexpressed in adenocarcinomas, a cancer subtype of NSCLC, and can lead to increased tumor resistance to chemotherapy. LP-300 can inhibit activity of TRX and GRX, restoring the redox balance of cancer cells and improving their sensitivity to chemotherapy.

08:04 EDT Jack Henry, MasterCard expand collaboration - Jack Henry (JKHY) announced an expansion of its existing relationship with Mastercard (MA) that will enable credit unions and banks to provide their accountholders the ability to securely see all of their financial accounts - within and outside their primary financial institution - in one place. Together, the companies establish a partnership that makes secure, API-based data-gathering affordable for community and regional financial institutions. Jack Henry will provide this consolidated view of data through Mastercard's open banking platform with certain services delivered through Finicity, a Mastercard subsidiary. This will help enable consumers and businesses to make more informed financial decisions and place community and regional financial institutions at the center of their accountholders' financial lives.

08:04 EDT Satellogic promotes Matt Tirman to chief commercial officer - Satellogic announced Matt Tirman has been promoted to chief commercial officer, Ignacio Zuleta has joined as the new VP of product imagery platform, and Sebastien Prioris has been added as VP of product platform applications. Tirman joined Satellogic in 2021 as president of Satellogic North America, the company's U.S. subsidiary pursuing business with the U.S. and Canadian public sector. As chief commercial officer, Tirman will lead Satellogic's worldwide go-to-market efforts across marketing, sales, and customer success. In this role he will guide the company through its most significant period of growth and advancements in commercializing high resolution EO data to customers across the global public and commercial markets.

07:58 EDT SL Green Realty, Caesars pursue gaming license for Times Square - SL Green Realty Corp. (SLG) and Caesars Entertainment (CZR) announced a partnership to redevelop 1515 Broadway as a premiere entertainment and gaming destination in the heart of Times Square. Caesars Palace Times Square will not only provide billions in tax revenue to New York City and State, it will also accelerate New York's economic recovery through strategic partnerships with area businesses utilizing its industry-leading loyalty program Caesars Rewards, home to more than 65 million members. Caesars Rewards members will be able to use credits at Broadway shows, local hotels, restaurants, retail stores, comedy clubs, entertainment venues, and more, driving more tourists to area businesses and creating thousands of direct and indirect jobs in and around Times Square

07:47 EDT Union Pacific reports Q3 business volumes up 3% - Business volumes, as measured by total revenue carloads, were up 3%.

07:46 EDT Lexagene Holdings signs statement of work with biopharma company - LexaGene Holdings announced that it has signed a statement of work with the same biopharma company that purchased a System last week.

07:42 EDT The Hanover estimates Q3 catastrophe losses $90M - The Hanover announced a preliminary estimate for Q3 catastrophe losses of approximately $90M, before taxes, or 6.8 points of net earned premiums. The estimate is approximately $22M above the company's pre-tax Q3 catastrophe assumption, driven primarily by the effects of Hurricane Ian. Estimated catastrophe losses from Hurricane Ian are approximately $28M, before taxes. CEO John Roche stated, "The strategic actions we have taken in the past reduced our exposure in coastal areas and helped mitigate the loss impact on our company from this storm." The Hanover's Q3 results were also impacted by elevated ex-CAT loss activity in the company's Personal and commercial multiple peril property lines, largely stemming from ongoing inflationary pressures, as well as property large losses in CMP. As a result, the company expects its Q3 current accident year loss and LAE ratio, excluding catastrophes, and its combined ratio, excluding catastrophes, to be 64.1% and 94.2%, respectively.

07:40 EDT Philip Morris: Total revised offer for Swedish Match is approx. SEK 176.4B

07:39 EDT Philip Morris says will not further increase offer for Swedish Match

07:39 EDT Palatin enrolls first patient in Phase 2 trial of ulcerative colitis candidate - Palatin Technologies announced that the first patient has been enrolled in the PL8177-205 study with Palatin's PL8177, an oral formulation of the melanocortin-1 receptor agonist, in patients with ulcerative colitis. The PL8177-205 interim assessment is currently expected to occur in 1Q23, with final topline data anticipated in 3Q23. The efficacy evaluations and endpoints are in line with the latest FDA Draft Guidance for Industry: Ulcerative Colitis: Developing Drugs for Treatment.

07:39 EDT Ayr Wellness introduces national portfolio of brands to New Jersey - Ayr Wellness announced the rollout of several brands from its national portfolio to the New Jersey market. New Jersey cannabis consumers can now purchase products from brands including Lost in Translation; Kynd; Road Tripper; STIX; Secret Orchard; and Wicked. All brands, with the exception of Kynd and Road Tripper, are currently available to both medical patients and adult-use consumers. "Since acquiring Garden State Dispensary, it has been Ayr's mission to provide an elevated experience for all New Jersey patients and consumers. The introduction of our portfolio of high-quality brands to our menus marks a major milestone in carrying out that mission," said Jonathan Sandelman, Founder and CEO of Ayr Wellness. "We know that our customers have diverse wants and needs, and it's important to us that we meet them wherever they are in their cannabis journey."

07:37 EDT Prize to go public via merger with Rose Hill Acquisition - Rose Hill Acquisition (ROSE) and Inversiones e Inmobilaria GHC Ltda announced that they have entered into a definitive business combination agreement that is expected to result in Prize (PRZE) becoming a U.S. publicly listed company with an initial enterprise value of approximately $425M. The proposed transaction is expected to close in the first quarter of 2023 and is subject to the satisfaction of customary closing conditions. As a result of the business combination, Prize and Rose Hill shareholders will exchange their shares for shares in a new combined company, which is expected to be publicly listed on the Nasdaq Global Market. The combined company will be the first Chilean enterprise to initially list directly on a U.S. Exchange, representing the start of a new wave of opportunities for investors abroad to access rapidly growing, profitable Latin American enterprises. Upon closing, the combined company expects its ordinary shares and warrants to trade on Nasdaq under the ticker symbols "PRZE" and "PRZE WS", respectively. In addition, Rose Hill has entered into a definitive $150M Standby Equity Purchase Agreement with Yorkville Advisors as an additional equity financing source for future opportunistic expansion for the combined company.

07:36 EDT GeoPark says Q3 consolidated oil and gas production up 8% to 38,396 boepd - Says on track to reach 2022 full-year guidance of 38,500-40,500 boepd.

07:34 EDT Watsco raises annual dividend 11% to $9.80 per share - Watsco announced that its Board of Directors has approved an 11% increase in its annual dividend to $9.80 per share on each outstanding share of its Common and Class B common stock. The increase will be reflected in the Company's quarterly dividend payment beginning in January 2023.

07:21 EDT Laser Photonics completes order for U.S. Navy - Laser Photonics announced the delivery of the CleanTech Handheld LPC-1000CTH to the U.S. Navy Kingsbay Trident Re-fit Facility, announced on October 11, 2022.

07:17 EDT Scynexis CEO Marco Taglietti to retire, David Angulo to succeed - SCYNEXIS reported the following changes to its executive leadership team: Marco Taglietti, after more than seven years leading the company, announced plans to retire at the end of the year. He will leave his position as SCYNEXIS' President and CEO and will step down from the Board of Directors on December 31, 2022. David Angulo, M.D., who has served as Chief Medical Officer for the past seven years, will become President and CEO of SCYNEXIS and join the Board of Directors, effective January 1, 2023. Ivor Macleod will join SYNEXIS as CFO on October 24, 2022. Mr. Macleod has more than 30 years of experience in the life sciences industry, including most recently as CFO of Athersys, Inc. With the shift in corporate priorities, the role of Chief Commercial Officer will be eliminated, and Christine Coyne, who has served in this leadership role for more than a year, will transition from the Company to pursue other opportunities.

07:16 EDT Amprius Technologies awarded a $50M cost sharing grant from the U.S. DOE - Amprius Technologies was awarded a $50M cost sharing grant from the U.S. Department of Energy "DOE's Office of Manufacturing and Energy Supply Chains MESC. Amprius is among the first set of companies to receive funding from President Biden's Bipartisan Infrastructure Law to expand domestic manufacturing of batteries for electric vehicles and the electrical grid, whose focus is on U.S.-based processing of materials and components. "Being among the first companies to receive a cost sharing grant from President Biden's Bipartisan InfrastructureLaw reflects the significant work Amprius is doing to advance the lithium-ion battery industry here in the U.S.," said Dr. Kang Sun, Chief Executive Officer of Amprius. "Our innovative technology was conceived at Stanford, designed and commercialized in the U.S., and now we are working to scale production capabilities to meet significant domestic demand and to accelerate the electrification of mobility with our ultra-high density silicon nanowire anode lithium-ion batteries." Amprius' objective is to demonstrate the manufacturing of silicon nanowire anode technology at the component and cell level on multi-megawatt-hour -scale manufacturing lines that are comparable to those used in multi-gigawatt-hour factories. This demonstration is expected to bring to maturity Amprius' manufacturing capabilities through the installation and operation of the first-of-its-kind large-scale production line for its ultra-high energy density batteries. This project is also expected to provide a bottom-up analysis of the cost factors of the demonstration line and product performance associated with the factory output. The tentative location for Amprius' demonstration factory is expected to be in Texas, among potential sites that include Georgia. Amprius' current level of battery performance, based on pilot production, indicates that Amprius will be able to deliver battery cells using its proprietary anode technology that have a specific energy and energy density that approach 2X the performance of current commercially available graphite cells. Amprius' commercially available batteries deliver up to 450 Wh/kg and 1,150 Wh/L, the industry's highest known energy density cells available on the market today.

07:14 EDT Gilat selected by Sencinet for Petrobras' oil, gas industry satellite project - Gilat Satellite Networks (GILT) announced that the Company was selected by Sencinet for Petrobras' (PBR) oil and gas industry satellite connectivity project. Petrobras, Brazil's largest oil and gas company, is modernizing and expanding its onshore/offshore telecommunications capabilities with satellite connectivity solutions powered by Gilat's SkyEdge II-c SATCOM network. Sencinet is deploying Gilat's SkyEdge II-c within offshore platforms, ships, and land stations as part of the innovative managed services satellite connectivity project they are providing to Petrobras. "I am pleased with the opportunity to expand and modernize Petrobras' legacy network, helping Petrobras address today's most demanding and complex business communication challenges," said Michal Aharonov, Chief Commercial Officer at Gilat. "Working together with Sencinet, our valued partner in the region, we're able to deploy Gilat's SkyEdge II-c multi-service platform to deliver a wide range of benefits to the oil and gas industry, as well as to other important markets in Latin America."

07:13 EDT Societal CDMO announces signing of two new CDMO service agreements - Societal CDMO announced that it has signed contract development and manufacturing organization, CDMO, service agreements with two new customers. These contracts are focused on a range of analytical method, technical transfer, formulation, manufacturing and packaging services designed to support ongoing development programs for novel therapeutic candidates. Under terms of the first new contract, Societal CDMO will provide services to support the ongoing clinical development of a modified release, bead-filled capsule formulation of an oral biologic indicated for pancreatic insufficiency. Societal CDMO's activities will support a planned Phase 3 clinical trial as part of the customer's ongoing clinical development program for the drug in the United States. As part of the second agreement, Societal CDMO will conduct a range of activities supporting a new customer's development of a novel interleukin-2 analog for the treatment of cancer. The services provided by Societal CDMO will include formulation development, analytical method transfer and verification, and GMP batch manufacturing and fill/finish related to the program, which is currently in preclinical development.

07:11 EDT Axsome Therapeutics announces availability of AUVELITY in U.S. - Axsome Therapeutics announced that AUVELITY is now available by prescription in the United States for the treatment of major depressive disorder, MDD, in adults. AUVELITY is the first and only oral N-methyl D-aspartate receptor antagonist approved for the treatment of MDD, and the first and only rapid-acting oral medicine approved for the treatment of MDD with labeling of statistically significant antidepressant efficacy compared to placebo starting at one week.1-4 AUVELITY was developed with FDA Breakthrough Therapy designation for the treatment of MDD. Lori Englebert, Executive Vice President, Commercial and Business Development of Axsome said, "Our highly experienced field team has begun active engagement with healthcare providers and are utilizing our first-in-class Digital Centric Commercialization, or DCC, platform. In clinical trials, Auvelity has demonstrated symptom improvement starting at one week, followed by achievement of remission in a substantial proportion of treated patients with major depressive disorder."

07:10 EDT KeyCorp sees Q4 NII up 4%-6%, noninterest income up 1%-3% - Sees Q4 loans up 2%-4%, deposits up 1%-3%. Sees Q4 noninterest expense up 1%-3%, with net chargeoffs at the lower end of the 15-25 bps range and a GAAP tax rate of about 19%.

07:08 EDT Talaris says DMC recommends dosing continue in FREEDOM-1 study after death - Talaris Therapeutics announced a status update on its Phase 3 FREEDOM-1 study in living donor kidney transplant recipients. On October 18, 2022, the Company received a report of a patient death, which triggered a pre-specified, temporary stopping requirement and review by the FREEDOM-1 Data Monitoring Committee. After their review of this case, the DMC determined that trial enrollment and dosing may continue. The Company has reported this event and the DMC's recommendation to the U.S. Food and Drug Administration. The deceased patient was one of three study subjects reported in June 2022 to have been diagnosed with grade II acute graft-vs-host disease. As reported, this patient was also diagnosed with moderate chronic GvHD that was responding to treatment at the time of the update. The patient was recently hospitalized with grade IV GvHD that was complicated by serious infections leading to respiratory and renal failure, and ultimately death. In June 2022, the Company provided a clinical update on its FREEDOM-1 study and summarized an amendment to the trial protocol following a review of all GvHD cases to date, spanning its Phase 2 and Phase 3 studies. The Company reported that the incidence of GvHD in FCR001 subjects was correlated with high CD34+ cell counts and high total nucleated cell counts in the FCR001 product. It also noted a correlation between the use of plerixafor as a donor mobilizing agent and an increased risk of GvHD, as plerixafor significantly increased CD34+ and total nucleated cell counts in the FCR001 product. The Company introduced two risk mitigation measures for GvHD in the amended trial protocol: elimination of plerixafor as a donor mobilizing agent, and addition of a second post-transplant dose of cyclophosphamide, which has been demonstrated to reduce the risk of severe GvHD in haplo-identical allogeneic hematopoietic stem cell transplants. The deceased patient had a related, same-sex donor with an HLA mismatch of 2/6. Although plerixafor was not used to mobilize this donor, the starting FCR001 material contained a high number of CD34+ cells and total nucleated cells, both of which had been identified by the Company during its review as factors that correlated with an increased risk of GvHD. The patient had not received a second post-transplant dose of cyclophosphamide as the patient was treated prior to the June 2022 protocol amendment. At the date of this update, the other two FREEDOM-1 patients who were previously reported to have had grade II aGvHD have experienced complete resolution of their aGvHD symptoms, although one patient experienced additional flares that were also responsive to treatment. After reviewing the facts of this case, the DMC concluded that the FREEDOM-1 protocol modifications implemented in June 2022 should be sufficient to mitigate the risk of GvHD going forward, and recommended continuation of the study without further modifications.

07:07 EDT Shutterstock adds Filmpac video collection - Shutterstock announced its partnership with Filmpac, a premium footage boutique, to bring Filmpac's cinema-quality video collection to Pond5 and Shutterstock. Filmpac's creative platform features 4K video content produced by cinematographers and artists, a library of approximately 100,000 video assets across 15 curated collections. Filmpac's exclusive content will be made available to both Enterprise and E-commerce customers across both Shutterstock and Pond5, initially as part of Shutterstock's Select collection and as part of Pond5's Marquee collection, which will be sold on an a-la-carte basis.

07:04 EDT Ginkgo Bioworks collaborates with Bolt Threads for optimization of Mylo material - Ginkgo Bioworks and Bolt Threads, a biotechnology and materials company, announced a multi-project collaboration to increase the production efficiency and performance of Bolt's current portfolio as well as expand it by developing novel proteins for biomaterials. The first program in this collaboration aims to optimize the production efficiency of Bolt's Mylomaterial, a leather alternative made out of mycelium, the underground root-like system of fungi. Mylo is an animal-free, sustainable alternative to leather grown from mycelium. Through Bolt Threads' production process, mycelium grows into a foamy layer that, once harvested, can be dyed and processed into sheets of material that can be customized to desired size, color, shape and thicknesses. Through this collaboration, Ginkgo aims to increase the growth rate of Bolt's mycelium, lowering the overall production costs of Mylo.

07:01 EDT UBS, Microsoft announce landmark expansion of cloud partnership - UBS (UBS) and Microsoft (MSFT) announced a landmark expansion of their partnership to accelerate UBS's public cloud footprint over the next five years. Through this transformational initiative, UBS plans to have more than 50% of its applications, including critical workloads, running on Microsoft Azure, now UBS's primary cloud platform. The partnership furthers UBS's "cloud-first" strategy and the modernization of its global technology estate. Through this partnership, UBS will have access to the most comprehensive cloud platform, trusted by more than 95% of Fortune 500 companies, with a rich set of productivity and collaboration tools, enabling the firm to increase the speed at which it can deliver and improve upon its digital experiences for clients and employees. At the same time, Azure will help advance UBS's sustainability initiatives, drive operational efficiencies, and maintain its standards for compliance and security - providing strong foundations on which to scale UBS's rate of cloud adoption.

06:51 EDT Immuneering names Leah Neufeld as Chief People Officer - Immuneering announced the appointment of Leah Neufeld to the newly created position of Chief People Officer, effective immediately. Neufeld joins Immuneering from Luzsana Biotechnology, where, since August 2021, she served as Chief Human Resources Officer, and as part of the executive team, helped establish Luzsana globally as a subsidiary of Hengrui Medicines, the largest Pharma company in China.

06:43 EDT Dover says reducing output in several businesses to draw down inventory balances - The company said, "Demand remains constructive across most of the portfolio and our order backlog remains at double its historical level relative to sales. The supply chain challenges that we have endured for the past 18 months continued to improve in the quarter which has allowed us to deplete our backlog at a faster rate and reduce our order conversion lead times closer to pre-pandemic levels. It is our expectation that this will continue for the balance of the year. Our full year outlook for cash generation remains robust, further strengthening our balance sheet position. Despite the macroeconomic uncertainty we are deploying capital to drive productivity and expand capacity in several businesses that are expected to deliver robust growth on secular tailwinds, and we are continuing to pursue attractive bolt-on acquisitions. During the quarter we also announced an accelerated share repurchase program to return excess capital to shareholders while preserving sufficient liquidity for value-creating investments. While current demand conditions are solid, our current management posture reflects growing caution in the macroeconomic outlook. As such, through the balance of the year we will be proactively reducing output in several businesses to draw down inventory balances and initiating cost containment measures where appropriate. Our business model is flexible, and we firmly believe that ongoing improvements in the supply chain will allow us to match production to meet demand within prevailing lead times in 2023. As we enter the final quarter of the year, I am confident in our team's ability to continue to outperform in a challenging operating environment. We remain committed to delivering results in line with our 2022 full-year guidance."

06:38 EDT AT&T says on track to achieve more than $4B of cost savings by year end - On track to achieve more than $4B of the $6B run-rate cost savings target by end of year.

06:33 EDT AT&T sees FY wireless service revenue growth in the upper end of 4.5%-5% - "We're investing at record levels to enhance our 5G and fiber connectivity and to deliver the best experience available in the market," said John Stankey, AT&T CEO. "Our results show our strategy is resonating with customers as we continue to see robust levels of postpaid phone net adds and approach 1 million AT&T Fiber net adds for the year. Our disciplined go-to-market approach is helping drive healthy subscriber growth with high-quality customers. As a result, we now expect to achieve wireless service revenue growth in the upper end of the 4.5 percent to 5 percent range. We remain confident in our ability to achieve, or surpass, all our financial commitments for the year, while still investing to bring our customers the industry's best services."

06:30 EDT AT&T reports Q3 cash from continuing operations $10.1B

06:23 EDT Warner Bros. Discovery announces 'The Lord of the Rings' Web3 Movie Experience - Warner Bros., in partnership with Content Blockchain pioneer Eluvio, announced the launch of the WB Movieverse with the The Lord of the Rings: The Fellowship of the Ring Web3 Movie Experience, available for preview opening for purchase on October 21. The Lord of the Rings: The Followship of the Ring Web3 Movie Experience is a multimedia living NFT, a new way for fans to engage with the film through two dynamic menu experience options, The Mystery Edition and The Epic Edition. Both allow owners to watch the extended version of the film in 4K UHD, access more than eight hours of special features, view image galleries, discover hidden AR collectibles, and explore themed navigation menus based on iconic locations from the beloved film, as well as own and trade the experience in a community marketplace.

06:13 EDT SpikImm enters non-exclusive in-license agreement with Xencor - SpikImm is developing two antibodies in parallel, SPK001 and SPK002, which have demonstrated potent neutralizing activity in vitro against SARS-CoV-2 and its variants of concern, and excellent therapeutic efficacy in vivo in reference animal models. SpikImm has entered into a non-exclusive in-license agreement with Xencor on the Xtend technology, designed to increase the half-life of its SPK001 and SPK002 antibodies and therefore, reduce the frequency of administration for optimal and convenient patient prophylaxis. SPK001 and SPK002 are among the most promising monoclonal antibodies against SARS-CoV2 in the world. Recruitment of the four volunteer cohorts is scheduled to be completed by the end of October 2022. SpikImm plans to evaluate the medical benefit of SPK001 and SPK002 in a Phase 2 trial in immunocompromised patients. Depending on the results, SpikImm could seek early access and emergency use1 approval as early as the second quarter of 2023.

06:06 EDT Dow Inc. expects dynamic macro environment in the near term - "In the near-term, we expect the macro environment to remain dynamic. As a result, we have outlined a playbook of actions that have the potential to deliver more than $1 billion in cost savings in 2023 while we continue to leverage our scale, geographic diversity and feedstock and derivative flexibility," said Fitterling. "At the same time, we remain focused on advancing our Decarbonize and Grow strategy with higher-return investments that will extend our competitive advantages and industry leadership positions. Our strong financial position and balance sheet as well as our continued focus on cash flow generation give us ample flexibility to execute on our capital allocation priorities, including attractive shareholder remuneration, as we maximize value creation over the longer-term."

06:04 EDT Walmart U.S. CEO says stores being open on Thanksiving a 'thing of the past' - Walmart U.S. CEO John Furner told The Today Show on Wednesday that its stores will be closed on Thanksgiving day. "It's a thing of the past," he said. "We'll be closed again on Thanksgiving. Fortunately, all of our associates will be able to spend time with their loved ones this year." Reference Link

05:51 EDT Musk says 'obviously overpaying' for Twitter, but 'excited' about situation - Tesla (TSLA) CEO Elon Musk said on the company's Q3 earnings call on Wednesday that he is "obviously overpaying" for Twitter (TWTR), but is "excited" about the situation. "Though myself and the other investors are obviously overpaying for Twitter right now, the long-term potential for Twitter is an order of magnitude greater than its current value," Musk said.

05:24 EDT Mercedes-Benz finalizes lithium supply agreement with Rock Tech Lithium - Mercedes-Benz finalized a supply agreement with Canadian-German-start-up Rock Tech Lithium to secure lithium used in battery production as part of a direct sourcing approach. Starting in 2026, including a qualification period, this allows the Stuttgart-based luxury carmaker to get its battery partners supplied with raw material to rapidly scale up its production of fully electric vehicles. Mercedes-Benz plans to go all electric by the end of the decade, wherever market conditions allow, requiring the brand with the three-pointed star to open new sources of raw materials with new partners. As part of the agreement, Rock Tech Lithium plans to supply battery-grade lithium hydroxide to Mercedes-Benz battery partners from a converter based in Guben, Brandenburg, Germany. Lithium hydroxide is needed for the production of lithium-ion batteries which are used in Mercedes-Benz electric vehicles.

05:20 EDT Amazon expands legal efforts to shut down fake review brokers - Amazon has continued to expand its legal efforts to shut down fake review brokers, filing its first criminal complaint in Italy and its first lawsuit in Spain. These two legal proceedings, plus 10 other new lawsuits recently launched in the U.S., target bad actors that operate more than 11,000 websites and social media groups that attempt to orchestrate fake reviews on Amazon and other stores in exchange for money or free products. Amazon also sent warning letters to five websites based in Germany that were directing visitors to a fake review broker. All five websites have since agreed to stop this activity by signing a cease and desist letter.

05:15 EDT LyondellBasell, Shakti Plastic sign MoU to operate recycling plant in India - LyondellBasell and Shakti Plastic Industries, India's largest plastic scrap recycler and waste collection company, have signed a memorandum of understanding, or MoU, to form a joint venture to build and operate a fully-automated, mechanical recycling plant in India. The plant is intended to process rigid packaging post-consumer waste and produce 50.000 tons of recycled polyethylene and polypropylene per year, equivalent to the single-use plastic waste produced by 12.5M citizens. It is envisaged that the new facility will become the largest mechanical recycling plant in India and is estimated to start at the end of 2024. LyondellBasell will market the recycled products produced by this joint venture adding volume to its Circulen Recover range of existing PE and PP materials to help meet increasing demand by converters and brand owners in India for recycled polymer materials.